Arvinas, Inc.
General ticker "ARVN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $803.0M (TTM average)
Arvinas, Inc. follows the US Stock Market performance with the rate: 36.2%.
Estimated limits based on current volatility of 2.7%: low 13.29$, high 14.03$
Factors to consider:
- Total employees count: 430 as of 2024
- Top business risk factors: Regulatory and compliance, Cybersecurity threats, Market volatility, Stockholder dilution, Strategic risks and growth management
- Price in estimated range
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.83$, 23.95$]
- 2025-12-31 to 2026-12-31 estimated range: [7.79$, 19.31$]
Financial Metrics affecting the ARVN estimates:
- Negative: with PPE of -6.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.29 <= 0.01
- Positive: 42.68 < Shareholder equity ratio, % of 51.47 <= 64.29
- Positive: Investing cash flow per share per price, % of 2.58 > -0.63
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ARVN quotes
Long-term ARVN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $131.40MM | $78.50MM | $263.40MM |
| Operating Expenses | $394.60MM | $480.00MM | $513.60MM |
| Operating Income | $-263.20MM | $-401.50MM | $-250.20MM |
| Non-Operating Income | $12.20MM | $37.60MM | $51.90MM |
| R&D Expense | $315.00MM | $379.70MM | $348.20MM |
| Income(Loss) | $-251.00MM | $-363.90MM | $-198.30MM |
| Taxes | $20.90MM | $0.90MM | $0.60MM |
| Profit(Loss)* | $-282.50MM | $-367.30MM | $-198.90MM |
| Stockholders Equity | $564.90MM | $660.00MM | $561.70MM |
| Assets | $1,268.80MM | $1,304.60MM | $1,091.40MM |
| Operating Cash Flow | $-273.50MM | $-347.80MM | $-259.30MM |
| Capital expenditure | $6.80MM | $2.90MM | $1.80MM |
| Investing Cash Flow | $242.80MM | $203.50MM | $34.70MM |
| Financing Cash Flow | $4.70MM | $374.70MM | $7.90MM |
| Earnings Per Share** | $-5.31 | $-6.62 | $-2.77 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.